Table XW1: Transfusion — Anatomical Regions

Putting in blood or blood products

Row 1

• Body Part: 3 Peripheral Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: 2 Plasma, Convalescent (Nonautologous)
• Qualifier: 5 New Technology Group 5

Row 2

• Body Part: 3 Peripheral Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: 7 Marnetegragene Autotemcel
• Qualifier: A New Technology Group 10

Row 3

• Body Part: 3 Peripheral Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: B Betibeglogene Autotemcel; C Omidubicel
• Qualifier: 8 New Technology Group 8

Row 4

• Body Part: 3 Peripheral Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: D High-Dose Intravenous Immune Globulin; E Hyperimmune Globulin
• Qualifier: 7 New Technology Group 7

Row 5

• Body Part: 3 Peripheral Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: F OTL-103; G Atidarsagene Autotemcel
• Qualifier: 8 New Technology Group 8

Row 6

• Body Part: 3 Peripheral Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: H Lovotibeglogene Autotemcel
• Qualifier: 9 New Technology Group 9

Row 7

• Body Part: 3 Peripheral Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: J Exagamglogene Autotemcel
• Qualifier: 8 New Technology Group 8

Row 8

• Body Part: 3 Peripheral Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: S Mozafancogene Autotemcel; Y Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable
• Qualifier: B New Technology Group 11

Row 9

• Body Part: 4 Central Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: 2 Plasma, Convalescent (Nonautologous)
• Qualifier: 5 New Technology Group 5

Row 10

• Body Part: 4 Central Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: 7 Marnetegragene Autotemcel
• Qualifier: A New Technology Group 10

Row 11

• Body Part: 4 Central Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: B Betibeglogene Autotemcel; C Omidubicel
• Qualifier: 8 New Technology Group 8

Row 12

• Body Part: 4 Central Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: D High-Dose Intravenous Immune Globulin; E Hyperimmune Globulin
• Qualifier: 7 New Technology Group 7

Row 13

• Body Part: 4 Central Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: F OTL-103; G Atidarsagene Autotemcel
• Qualifier: 8 New Technology Group 8

Row 14

• Body Part: 4 Central Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: H Lovotibeglogene Autotemcel
• Qualifier: 9 New Technology Group 9

Row 15

• Body Part: 4 Central Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: J Exagamglogene Autotemcel
• Qualifier: 8 New Technology Group 8

Row 16

• Body Part: 4 Central Vein
• Approach: 3 Percutaneous
• Device / Substance / Technology: S Mozafancogene Autotemcel; Y Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable
• Qualifier: B New Technology Group 11